drugset / Trial / NCT04536272
Reduced Anticoagulation Targets in ECLS (RATE)
Phase 3
Completed
330 enrolled
University Medical Center Groningen
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · collabErasmus Medical Center · collabIsala · collabLeiden University Medical Center · collabOLVG · collabRadboud University Medical Center · collabSt. Antonius Hospital · collabZonMw: The Netherlands Organisation for Health Research and Development · collab
RandomizedParallel-groupOpen-labelOther
Summary
The objective of the RATE-trial is to study if reduced anticoagulation targets during ECLS diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2025-03-07
- Completion
- 2025-03-07
Publications
- Minnen OV, Lansink-Hartgring AO, van Amstel RBE, van den Bogaard B, Bunge JJH, Delnoij TSR, Droogh JM, Koppenhagen LV, Kraemer CVE, Kuijpers M, Maas JJ, Metz J, van de Poll MCG, Raasveld SJ, Dos Reis Miranda D, Vart P, Vermeulen KM, Vlaar APJ, van den Bergh WM; Dutch ECLS Study Group. Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial. Lancet. 2026 Jul 7:S0140-6736(26)00851-2. doi: 10.1016/S0140-6736(26)00851-2. Online ahead of print.
- Vlasma JR, Fan Y, van der Velde P, Metz E, Lansink AO, Hoffmann RF, Nawijn MC, Burgess JK, Pillay J. Myeloid Cell Differentiation Within Extracorporeal Membrane Oxygenators in Patients With Acute Respiratory Distress Syndrome. ASAIO J. 2026 Jun 1;72(6):e89-e91. doi: 10.1097/MAT.0000000000002650. Epub 2026 Jan 13. No abstract available.
- van Minnen O, Linde M, Oude Lansink-Hartgring A, van den Boogaard B, Bunge JJH, Delnoij TSR, Elzo Kraemer CV, Kuijpers M, Maas JJ, de Metz J, van de Poll M, Dos Reis Miranda D, Vlaar APJ, van Ravenzwaaij D, van den Bergh WM. Reduced anticoagulation targets in extracorporeal life support (RATE): protocol for a pre-planned secondary Bayesian analysis of the rate trial. Trials. 2025 Mar 15;26(1):90. doi: 10.1186/s13063-025-08737-6.
- van Minnen O, Oude Lansink-Hartgring A, van den Boogaard B, van den Brule J, Bulpa P, Bunge JJH, Delnoij TSR, Elzo Kraemer CV, Kuijpers M, Lambermont B, Maas JJ, de Metz J, Michaux I, van de Pol I, van de Poll M, Raasveld SJ, Raes M, Dos Reis Miranda D, Scholten E, Simonet O, Taccone FS, Vallot F, Vlaar APJ, van den Bergh WM. Reduced anticoagulation targets in extracorporeal life support (RATE): study protocol for a randomized controlled trial. Trials. 2022 May 16;23(1):405. doi: 10.1186/s13063-022-06367-w.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dalteparin sodium | Other / unclassified | — | Subcutaneous |
| Comparator | Enoxaparin sodium | Other / unclassified | — | Subcutaneous |
| Comparator | Heparin | Other / unclassified | — | Intravenous |